Key result
The 6th World Symposium on Pulmonary Hypertension revised the hemodynamic definition of pulmonary hypertension to a mean pulmonary artery pressure >20 mmHg.
Why the study?
Major advances have occurred in pulmonary hypertension over the past 20 years, prompting the 6th World Symposium in Pulmonary Hypertension to consolidate knowledge into practical recommendations and updated treatment algorithms.
This review provides a comprehensive summary of the 6th World Symposium in Pulmonary Hypertension, highlighting updated definitions, classifications, and treatment algorithms.
Adopts lower mPAP threshold for PH diagnosis; leaves open prospective validation of outcomes and treatment thresholds.
The past 20 years have seen major advances in the diagnosis and management of pulmonary hypertension, a disease associated with significant morbidity and mortality. The 6th World Symposium in Pulmonary Hypertension (WSPH) took place in February 2018 and attempted to consolidate the current knowledge in the field into practical recommendations to help prioritize an action plan to improve patient outcomes and identify future research directions. In this review, we will summarize the highlights of the 6th WSPH proceedings, including revisions to the hemodynamic definitions and classification of the various types of pulmonary hypertension, genetic advances, approaches to risk stratification, and updated treatment algorithms.
No takes yet. Share an insight, caveat, or question.
Thomas et al. (2019) conducted a review in Pulmonary hypertension. The 6th World Symposium on Pulmonary Hypertension revised the hemodynamic definition of pulmonary hypertension to a mean pulmonary artery pressure >20 mmHg.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: